MSD boosts by 18.9% with Keytruda of KRW 7.7 trillion in sales
AZ shows even growth of TagrissoㆍImfinziㆍLynparzaㆍCalquence
[Newsmp] Despite facing a decline in the first quarter, the leading global pharmaceutical companies have showcased a sustained rise in the domain of anticancer drugs.
The first quarter reports of global pharmaceutical companies, compiled by Newsmp, indicate that while most firms reported a decline in growth, the anticancer drugs division showed continued growth.
While MSD's revenue declined by close to 10% in the last quarter compared to the same period the previous year, there was a significant growth of nearly 20% in its anticancer drug business.
Keytruda, a major contributor to the overall revenue of anticancer drugs, achieved sales of approximately KRW 7.7 trillion in the previous quarter, playing a key role in the significant growth of 20.5% in the anticancer drug division.
In spite of experiencing a decline of 4.5% in the preceding quarter, AstraZeneca's oncology division attained a remarkable revenue growth of 13.8%, surpassing the threshold of KRW 5 trillion with a double-digit expansion.
Amidst the continued growth of Tagrisso, other drugs such as Imfinzi, Lynparza, and Calquence have also contributed to the expansion of the anticancer drug division through consistent growth.
Novartis remained at a growth rate of 3.4% in the last quarter, but its anticancer drug division experienced significant growth of 25.1%.
Particularly, the solid tumor sector witnessed a surge of 49% in growth, primarily driven by breast cancer treatments Kisqali and Piqray. Simultaneously, the hematologic malignancies sector achieved growth in the double digits.
Johnson & Johnson (Janssen) was able to achieve a 4.1% growth in revenue for the anticancer drug division by offsetting the notable decrease in sales of Imbruvica and Zytiga with the success of Darzalex and Erleada.
Despite the growth of Venetoclax, AbbVie faced a significant decline in the sales of Imbruvica, resulting in a contraction of 14.0% in revenue for the hematologic malignancies sector.
Furthermore, Pfizer and GSK saw a marginal decline in revenue in the oncology division compared to the same period last year, while Lilly maintained the same level as the previous year.